ZFHX3

Across TCGA pan-cancer cohorts, ZFHX3 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ZFHX3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ZFHX3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZFHX3 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

HNSC, LIHC, and CHOL are the cancer types where ZFHX3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZFHX3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	III,IV	+1.346	<.001	12	view →
LIHC	All	II,III,IV	+0.670	<.001	8	view →
CHOL	Male	All	+1.631	<.001	5	view →
THCA	All	All	−0.405	.002	5	view →
KIRP	All	IV	+1.002	.027	2	view →
LUSC	Male	All	−0.315	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ZFHX3–HNSC

Open the HNSC breakdown →